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Platelet GMP-140 and CD40L as speciﬁc markers of platelet activation play an important role in the morbidity and development
of rheumatoid arthritis. The expression of GMP-140, CD40L increases in peripheral blood of AA rats. And they have correlation
with voix pedis’ swelling, AI. XFC could inhibit the inﬂammatory response through inhibiting platelet activation of AA rats, which
means decreasing the expression of GMP-140, CD40L in peripheral blood. So, the voix pedis’ swelling and AI were decreased as
the result.
1.Introduction
Studies show that platelet activation plays an important role
in the pathogenesis of rheumatoid arthritis [1–3]. Activation
of platelet releases and expresses a variety of activation
products to the membrane surface. These substances par-
ticipate in platelet-endothelial cell reaction and platelet-
l e u k o c y t er e a c t i o ni nd i ﬀerent ways and play an important
role in the occurrence and development of inﬂammation
and particularly, chronic inﬂammatory [4]. To explore the
mechanism of platelet activation in the pathogenesis of
rheumatoid arthritis, the rats were injected with Freund’s
complete adjuvant (FCA) as immune stimulation, to observe
the change of platelet GMP-140 and CD40L in peripheral
blood and eﬀects of Xinfeng Capsules (XFC) on them. The
result of study is as follows.
2.MaterialandMethods
2.1. Animals. 40 male clean degree SD rats, Anli laboratory
animals limited liability company of Anhui Province (certiﬁ-
cate number: 2010-0008), average weight (200 ±20)g.
2.2.MajorDrugsandReagents. Methotrexate(MTX):2.5mg
per tablet, Sine Pharmaceutical factory of Shanghai phar-
maceutical limited, batch number: 100923; tripterygium
wilfordiipolycorideTablet(TPT):10mgpertablet,Shanghai
Fudan Fuhua pharmaceutical industry limited, batch num-
ber: 100809. XFC: preparation centre of ﬁrst hospital aﬃli-
ated to Anhui College of Traditional Chinese Medicine, main
composition: coix seed, Astragalus, centipede, tripterygium
wilfordii, 0.4g per pill, batch number: 100521; FCA: USA
Sigma company, batch number: 065K7805; anti-rat GMP-
140 and CD40L monoclonal antibody labeled with Fluores-
cein Isothiocyanate (FITC): Beijing Bioss biotechnology Co.
Ltd, batch number: 100512 and 100419, Art. No. bs-1286R
and bs-0561R.
2.3. Major Instruments and Equipments. Beckman-Coulter
XL-ESPIC MCL-type Flow Cytometry.
2.4. Model and Administration. 40 SD male rats were
randomly divided into 5 groups after adaptable feeding 1
week, normal control group (n = 8), and model groups
(n = 32).Exceptfortheratsofnormalgroup,theotherswere2 International Journal of Rheumatology
intracutaneously injected with 0.1mL of Freund’s complete
adjuvant in the right hindlimb to model [5]. AA rats were
randomly divided into 4 groups and administrated at 20
times clinical dosage: model control group, MTX group,
TPT group, and XFC group after 19th day. (1) TPT group:
TPT was grinded into ﬁne powder and mixed with saline
to blending. The rats were intragastric administrated with
10mL/kg1timeeachday.(2)MTXgroup:MTXwasgrinded
into ﬁne powder and mixed with saline to blending. The
rats were intragastric administrated with 10mL/kg 1 times a
week, while they were given saline 10mL/kg 1 times each day
on the other days. (3) XFC group: XFC was grinded into ﬁne
powder without capsule and mixed with saline to blending.
The rats were intragastric administrated with 10mL/kg 1
times a day. (4) Normal control group and model control
group were given saline 10mL/kg 1 times each day. The rats
of each group were intragastric administrated for 30d.
2.5. The Voix Pedis’ Swelling. Left voix pedis volumes of
rats were measured on 1d before injection, 1d before
administration, and 30d after administration. The voix
pedis’ swelling was calculated [6]. The voix pedis’ swelling =
(Vt − Vn)/Vn × 100% (Vn, before injection; Vt,a f t e r
injection).
2.6. Arthritis Index (AI). Observe and record degree of
arthropathy on 12th, 1 time three day. The arthropathy was
appraised with 5-point method. AI was calculated according
to the other three limbs without injection [7]. 0 score: no
redness and swelling; 1 score: redness and swelling of little
toe joint; 2 score: swelling of toe and voix pedis joint; 3 score:
swelling of joints under ankle joint; 4 score: swelling of all
joints includes ankle joint; 5 score: integral accumulation of
each joint is AI of rats.
2.7. GMP-140. Blood was drawn to EDTA anticoagulant
tube and then centrifuged for 8 minutes at 1000r/min.
Platelet rich plasma (PRP) is plasma without liquid super-
natant.Thenaddinganti-ratGMP-140monoclonalantibody
labeled with FITC to it. And incubating for 15 minutes in
dark at room temperature. Adding 2mL 1% paraformalde-
hyde ﬁxative and putting it to ﬂow cytometry. Last, analyzing
GMP-140 positive expression with CeQuest.
2.8. CD40L. Adding anti-rat CD40L monoclonal antibody
labeled with FITC to 10μL blood with EDTA anticoagulant.
And incubating for 5 minutes in dark at room temperature.
Thencentrifugingfor5minutesat1000r/min.Andthrowing
away liquid supernatant. Adding phosphate buﬀer (PBS)
2mL and centrifuging for 5 minutes at 1000r/min. Throw-
ing away liquid supernatant. Mixing with PBS 300μLt o
blending. Putting it to ﬂow cytometry and analyzing CD40L
positive expression with CeQuest.
2.9. Statistics. Data were expressed as (x ± s)a n dt ob e
treated statistically with SPSS 11.5 for windows software.
After Kolmogorov-Smirnov Region Surrounding the Nansha
Islands, multiple groups means were compared with single-
factor analysis of variance, and the comparison among
groups was performed with LSD and SNK method. And
the samples were analyzed using the method of multivariate
correlation analysis.
3. Result
3.1. The Change of Weight of Each Group. The weight of
each group was no signiﬁcant diﬀerence before phlegmasia
(P>0.05). The weight of model group was signiﬁcantly
decreased than the normal group on 1 day before admin-
istration (P<0.05). Compared with the model group, the
weight of MTX, TPT, and XFC groups was signiﬁcantly
increased (P<0.01). The body mass in XFC-treated group
was signiﬁcantly higher than those in MTX and TPT groups
(P<0.05) (see Table 1).
3.2. The Change of the Voix Pedis’ Swelling and AI of Each
Group. The voix pedis’ swelling and AI of the model group
was signiﬁcantly increased than the normal group on 1 day
before administration (P<0.01). Compared with the model
group, there was no signiﬁcant diﬀerence in three treated
groups (P>0.05). After the 30th of administration, the
voix pedis’ swelling and AI of MTX, TPT, and XFC groups
was signiﬁcantly decreased than those in the model group
(P<0.01). There was no signiﬁcant diﬀerence among three
treated groups (P>0.05) (see Table 2).
3.3. The Change of GMP-140, CD40L of Each Group. The
GMP-140, CD40L, of the model group was signiﬁcantly
higher than the normal group (P<0.01). Compared with
the model group, the GMP-140 and CD40L of MTX, TPT
and XFC groups were signiﬁcantly decreased (P<0.01).
The GMP-140 of XFC showed a decreasing tendency with no
signiﬁcant diﬀerence than the MTX, TPT groups (P>0.05).
The CD40L showed no signiﬁcant diﬀerence among three
treated groups (P>0.05) (see Table 3 and Figures 1 and 2).
3.4. The Dependability between GMP-140, CD40L, and the
V o i xP e d i s ’S w e l l i n g ,A Io fR a t s .The expression of GMP-
140 and CD40L were positively correlated with voix pedis’
swelling and AI (P<0.01 or P<0.05) (see Table 4).
4. Discussion
Platelet GMP-140 and CD40L as speciﬁc markers of platelet
activation play an important role in the morbidity and
development of rheumatoid arthritis [8]. Studies show that
GMP-140 was the marker of RA activity and inﬂammatory
[9, 10]. Activated GMP-140 interacted with polymorphonu-
clear leukocyte ligand in circulation. Then inﬂammatory
cells were exuded to joint synovial tissues space and
produced immune response and inﬂammatory damage of
synovium. Inﬂammatory cells could release more GMP-140,
thus, in cycles, promoting the progression of RA and syn-
ovial inﬂammatory [11]. GMP-140 could activate synovial







































































Figure 1: GMP-140 of AA rats.
deposited in RA synovium. It caused joint swelling and
tissue injury [12]. CD40L plays an important role in the
occurrence and development of chronic synovitis. High level
e x p r e s s i o no fC D 4 0 Lh a sb e e nd e t e c t e di nR As y n o v i u m
[13].ExpressionofCD40Lonplateletcaninduceendothelial
cells to release chemotaxins and express adhesion molecules.
Thus producing a signal, which raises various inﬂammatory
mediators gathering in synovium. It causes hyperplasia of
synovial tissue, inﬂammation, damage of cartilage and bone
[14]. CD40L can also stimulate inﬂammation mononuclear
macrophages, which secrete vascular endothelial growth
factor,increase vascularpermeability, improve inﬂammatory
inﬁltration, and promote the growth and relocation of
endothelial cells, angiogenesis, and pannus formation [15].
In this experiment, it was shown that GMP-140 and CD40L
as platelet activation markers in peripheral blood of AA rats4 International Journal of Rheumatology
Table 1: Comparison of weight of each group (n = 8, x ±s,g ) .
Groups
Weight
Weight before phlegmasia Weight before administration Weight of the 30th of administration
Control 214.38 ±18.98 260.00 ±11.02 360.25 ±23.46
Model 211.88 ±17.31 226.25 ±35.73
∗ 260.50 ±37.20
∗∗
MTX 213.75 ±13.02 231.88 ±30.70
∗ 311.00 ±43.61
∗
TPT 212.50 ±11.95 230.00 ±14.88
∗ 317.63 ±32.51
∗
XFC 213.75 ±22.80 232.50 ±13.63
∗ 351.88 ±21.96
Note: compared with control group, ∗P < 0.05, ∗∗P < 0.01; compared with model group, P<0.01; compared with MTX group, P<0.05; compared
with TPT group, P < 0.05.
Table 2: Comparison of the voix pedis’ swelling, arthritis index of each group (n = 8, x ±s).
Groups
The voix pedis’ swelling AI
Weight before
administration




Weight of the 30th of
administration















∗∗ 41.57 ±15.28 7.88 ±0.64
∗∗ 3.50 ±1.07
∗∗
Note: compared with control group, ∗∗P < 0.01; compared with model group, P < 0.01.
Table 3: Comparison of GMP-140, CD40L of each group (n = 8,
x ±s,p g / m L ) .
Groups GMP-140 CD40L




MTX 0.55 ±0.27 95.47 ± 2.36
TPT 0.49 ±0.28 95.24 ± 1.90
XFC 0.38 ±0.20 95.39 ± 2.27
Note: compared with control group, ∗∗P < 0.01; compared with model
group, P < 0.01, P < 0.05.
Table 4: The dependability between GMP-140, CD40L, and the
voix pedis’ swelling, AI (n = 40).
GMP-140 CD40L
rP r P
The voix pedis’ swelling .608∗∗ .000 .441∗ .015
AI .611∗∗ .000 .386∗ .035
∗∗P < 0.01, ∗P < 0.05.
were signiﬁcantly increased. The reason was that activated
plateletinperipheralbloodofAAratsreleasesalargenumber
of activation products including platelet CD40L, GMP-140.
This study also discovered that GMP-140 and CD40L were
positively correlated with voix pedis’ swelling and AI (P<
0.01 or P<0.05). GMP-140 and CD40L as proinﬂammatory
mediators promote the occurrence and development of joint
synovitis and pannus formation. So, platelet GMP-140 and
CD40L have relevance with inﬂammatory markers.
XFC, which strengthens the spleen and replenishes Qi,
resolving Dampness and freeing channel, is a traditional
Chinese medicine compound preparation based on overall
regulation. Its main components are coix seed, astragalus,
tripterygium wilfordii, and centipede. They not only have
diﬀerent degrees of anti-inﬂammatory eﬀect but also inhibit
plateletactivation.Astragalushasobviousanti-inﬂammatory
eﬀects. Its mechanism could lie in decreasing the emergence
of oxyradical, inﬂammatory mediators including IL-8, TNF-
α, NO, and so on. And adding the expression of glucocor-
ticoid receptor under inﬂammation [16, 17], astragalus can
eﬀectively reduce the degree of platelet activation and inhibit
synthesis of platelet GMP-140. Modern study conﬁrmed that
itcouldobviouslyinhibitjointswellinginducedbyeggwhite,
granulomainducedbycottonball,andtheearedemainmice
induced by xylene. And it also could inhibit inﬂammatory
with inhibiting signiﬁcantly the synthesis and release of
prostaglandin E2 of inﬂammation [18]. Modern pharmaco-
logical studies show that tripterygium wilfordii had a strong
anti-inﬂammation eﬀect with inhibiting the expression of
IL-1β, IL-12, TNF-α, and secretion of NO and IL-6 from
macrophage [19–22]. Adjuvant arthritis rat blood was in
hyperviscosity and platelet hyperaggregation. Tripterygium
wilfordii could improve blood hyperviscosity and platelet
aggregation of AA rat, which assisted anti-inﬂammatory
eﬀect. The research shows that tripterygium wilfordii could
suppress immune by inhibiting expression of CD40L [23].
Centipede plays an anti-inﬂammatory eﬀect with improving
microcirculation, extending coagulation time, decreasing
hematocrit, reducing blood viscosity, increasing the num-
ber of opening microvascular, and increasing diameter of




































































































Figure 2: CD40L of AA rats.
The result from the experiment shows that XFC could
decrease the voix pedis’ swelling and AI of AA rats the same
as MTX, TPT. The body mass in XFC-treated group was
signiﬁcantly higher than those in MTX and TPT groups
because that astragalus in XFC could protect gastric mucosa
and inhibit gastrointestinal adverse reactions of tripterygium
wilfordii (P<0.05). It shows that XFC has the anti-
inﬂammatory eﬀects as MTX, TPT, and is superior to MTX
and TPT in improving overall function of AA rat. Content
of tripterygium wilfordii in XFC is lower than TPT. It
shows that XFC on the overall eﬀect in AA rat is better
than a separate application of TPT. And XFC could increase
eﬀect and inhibit toxic eﬀect of tripterygium wilfordii. With
the expression of GMP-140, CD40L in peripheral blood of
AA rats decreased by XFC; the voix pedis’ swelling and
AI also dropped. It indicated that XFC could inhibit the6 International Journal of Rheumatology
inﬂammatoryresponsethroughinhibitingplateletactivation
of AA rats, which means decreasing the expression of GMP-
140, CD40L in peripheral blood. So, the voix pedis’ swelling
and AI were decreased as the result.
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